vs
Side-by-side financial comparison of LXP Industrial Trust (LXP) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $86.7M, roughly 1.5× LXP Industrial Trust). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -14.0%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 0.3%).
LXP Industrial Trust is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality industrial real estate assets, primarily distribution centers, logistics facilities, and light industrial properties across key markets in the United States. Its tenant base covers e-commerce, third-party logistics, and advanced manufacturing sectors, delivering stable long-term returns for its investors.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
LXP vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.7M | $129.7M |
| Net Profit | $28.8M | — |
| Gross Margin | 81.5% | 98.0% |
| Operating Margin | 34.6% | -25.0% |
| Net Margin | 33.2% | — |
| Revenue YoY | -14.0% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.7M | $129.7M | ||
| Q3 25 | $86.9M | $164.9M | ||
| Q2 25 | $87.7M | $114.4M | ||
| Q1 25 | $88.9M | $81.7M | ||
| Q4 24 | $100.9M | $74.8M | ||
| Q3 24 | $85.6M | $62.9M | ||
| Q2 24 | $85.8M | $54.1M | ||
| Q1 24 | $86.3M | $41.4M |
| Q4 25 | $28.8M | — | ||
| Q3 25 | $36.3M | $25.7M | ||
| Q2 25 | $29.1M | $-12.8M | ||
| Q1 25 | $19.0M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.3M | $-54.8M | ||
| Q2 24 | $5.4M | $-70.4M | ||
| Q1 24 | $-269.0K | $-136.1M |
| Q4 25 | 81.5% | 98.0% | ||
| Q3 25 | 82.3% | 99.0% | ||
| Q2 25 | 81.9% | 98.7% | ||
| Q1 25 | 80.7% | 94.3% | ||
| Q4 24 | 85.3% | 96.6% | ||
| Q3 24 | 82.5% | 97.4% | ||
| Q2 24 | 82.0% | 96.2% | ||
| Q1 24 | 82.4% | 96.4% |
| Q4 25 | 34.6% | -25.0% | ||
| Q3 25 | 50.4% | 15.1% | ||
| Q2 25 | 33.7% | -11.1% | ||
| Q1 25 | 21.8% | -52.2% | ||
| Q4 24 | — | -81.2% | ||
| Q3 24 | 7.9% | -89.3% | ||
| Q2 24 | 6.9% | -125.1% | ||
| Q1 24 | 1.0% | -336.5% |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 41.7% | 15.6% | ||
| Q2 25 | 33.2% | -11.1% | ||
| Q1 25 | 21.4% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.4% | -87.1% | ||
| Q2 24 | 6.3% | -130.1% | ||
| Q1 24 | -0.3% | -328.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | $0.12 | $0.28 | ||
| Q2 25 | $0.09 | $-0.14 | ||
| Q1 25 | $0.06 | $-0.47 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $0.02 | $-0.70 | ||
| Q2 24 | $0.01 | $-0.91 | ||
| Q1 24 | $-0.01 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $170.4M | $93.0M |
| Total DebtLower is stronger | $1.4B | — |
| Stockholders' EquityBook value | $2.0B | $114.8M |
| Total Assets | $3.5B | $605.2M |
| Debt / EquityLower = less leverage | 0.66× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.4M | $93.0M | ||
| Q3 25 | $229.7M | $110.9M | ||
| Q2 25 | $71.0M | $75.2M | ||
| Q1 25 | $70.9M | $61.9M | ||
| Q4 24 | $101.8M | $58.5M | ||
| Q3 24 | $55.0M | $36.4M | ||
| Q2 24 | $48.7M | $32.3M | ||
| Q1 24 | $293.8M | $43.3M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.0B | $114.8M | ||
| Q3 25 | $2.1B | $73.6M | ||
| Q2 25 | $2.1B | $32.7M | ||
| Q1 25 | $2.1B | $32.8M | ||
| Q4 24 | $2.1B | $59.1M | ||
| Q3 24 | $2.1B | $-30.5M | ||
| Q2 24 | $2.1B | $15.1M | ||
| Q1 24 | $2.2B | $74.1M |
| Q4 25 | $3.5B | $605.2M | ||
| Q3 25 | $3.7B | $538.6M | ||
| Q2 25 | $3.7B | $555.3M | ||
| Q1 25 | $3.8B | $548.8M | ||
| Q4 24 | $3.8B | $594.1M | ||
| Q3 24 | $3.9B | $504.4M | ||
| Q2 24 | $3.9B | $551.1M | ||
| Q1 24 | $4.2B | $663.5M |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $188.7M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 6.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $188.7M | $60.7M | ||
| Q3 25 | $63.5M | $14.3M | ||
| Q2 25 | $44.3M | $5.0M | ||
| Q1 25 | $39.0M | $-42.2M | ||
| Q4 24 | $211.2M | $-35.7M | ||
| Q3 24 | $64.6M | $-42.5M | ||
| Q2 24 | $38.5M | $-40.2M | ||
| Q1 24 | $38.9M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 6.56× | — | ||
| Q3 25 | 1.75× | 0.56× | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | — | ||
| Q2 24 | 7.09× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LXP
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
